FDA Clearance Tracker · P030035-S138
FRONTIER/FRONTIER II/ANTHEM FAMILY OF CRT-PS
Last checked: Nov 20, 2026Latest source record: Feb 12, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Feb 12, 2016
Approved
Time to decision
179 days
Received Aug 17, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P030035-S138
- Device name
- FRONTIER/FRONTIER II/ANTHEM FAMILY OF CRT-PS
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Sylmar, CA
- Received
- Aug 17, 2015
- Decided
- Feb 12, 2016
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P030035
Device type
- Device type
- Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D) (NIK)
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval for Quadra Assura MP Cardiac Resynchronization Therapy devices (CRT-Ds) Models CD3269-40, CD3269-40Q, CD3369-40, CD3369-40Q, CD3369-40C, CD3369- 40QC; Quadra Allure MP Cardiac Resynchronization Therapy Pacemaker devices (CRT-Ps) Models PM3160 and PM3262; and Model 3330 Version 21.1 Software for the Model 3650 Merlin Patient Care System Programmer.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.